Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/7/2010

CAMBRIDGE, Mass., Sept. 7 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the Robert W. Baird Small Cap Healthcare Conference on Tuesday, September 14, 2010 at 9:30 a.m. ET at the St. Regis Hotel, New York City and at the Stifel Nicolaus Healthcare Conference on Thursday, September 16, 2010 at 11:30 a.m. ET at the Four Seasons Hotel, Boston.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived replay will be available on the Idenix website for two weeks following the conference.  

About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.Idenix Pharmaceuticals Contact:Jonae Barnes (617) 224-4485 (investors)Kelly Barry (617) 995-9033 (media)
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
2. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
3. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
7. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
10. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
11. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Eli Lilly and Company (NYSE: ... 3 EXPEDITION3 trial at the 9 th Clinical ... solanezumab did not meet the primary endpoint in the ... people with mild dementia due to Alzheimer,s disease (AD), ... for the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)... CAMBRIDGE, Mass. , Dec. 8, 2016 /PRNewswire/ ... today that Nationwide Children,s Hospital signed ... enhance and accelerate the development of new cures. ... healthcare organizations representing over 57 million patients globally, ... are working together to improve protocol design, site ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... ... STAT courier is pleased to announce that due to customer demand, as well ... presence in Dallas. One of the most exciting parts for STAT is that the ... and Forth Worth market. STAT takes pride in treating their employees with integrity and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne ... offices headquartered in Hamilton County, is embarking on a charity drive with the ... finding new homes for orphaned or neglected senior dogs in the Cincinnati region, ...
Breaking Medicine News(10 mins):